UCB S.A. / Neurona Therapeutics, Inc.

Drug-Resistant Mesial Temporal Lobe Epilepsy (MTLE)

3.4M US cases/yr · $11.0B Global epilepsy therapeutics market

Disease Overview

Mesial temporal lobe epilepsy (MTLE) is the most common form of focal epilepsy in adults and is frequently associated with hippocampal sclerosis — neuronal loss and gliosis in the hippocampus that drives hyperexcitability and recurrent focal-onset seizures, often with impaired awareness and secondary generalization. Approximately one-third of epilepsy patients are drug-resistant (fail ≥2 appropriately chosen antiseizure medications at tolerated doses), and MTLE is disproportionately represented in this refractory population. Drug-resistant MTLE imposes severe burden: uncontrolled seizures raise risks of SUDEP (sudden unexpected death in epilepsy), injury, cognitive decline, depression, and unemployment, with direct medical costs and indirect productivity losses that rival many oncology indications. Current surgical options — anterior temporal lobectomy, selective amygdalohippocampectomy, laser interstitial thermal therapy (LITT), and neurostimulation (RNS, DBS, VNS) — produce seizure freedom in 50-70% of appropriately selected candidates but carry risks of memory and language deficits, and many patients are ineligible or decline resection. Disease-modifying approaches addressing the underlying loss of GABAergic inhibitory tone in the epileptogenic hippocampus represent a meaningful unmet need. Neurona's NRTX-1001 delivers allogeneic GABAergic interneurons via single stereotactic injection to restore local inhibition without resection.

Competitive Landscape

The drug-resistant focal epilepsy competitive landscape is dominated by antiseizure medications (ASMs) spanning diverse MOAs: sodium-channel modulators (lacosamide, eslicarbazepine, oxcarbazepine, carbamazepine), SV2A ligands (UCB's Keppra/levetiracetam and Briviact/brivaracetam), GABAergic agents (clobazam, tiagabine, vigabatrin), AMPA receptor antagonists (perampanel), and multi-mechanism agents including UCB's Vimpat (lacosamide) and SK Biopharmaceuticals' Xcopri (cenobamate). Surgical and device competitors include NeuroPace's RNS System (responsive neurostimulation), Medtronic's DBS and Percept for epilepsy, LivaNova's VNS Therapy, and Medtronic Visualase / Monteris LITT ablation systems. Emerging disease-modifying approaches include Encoded Therapeutics' ETX101 (AAV-based SCN1A upregulation in Dravet), Stoke Therapeutics' zorevunersen (SCN1A antisense oligonucleotide in Dravet), Longboard Pharmaceuticals' bexicaserin, and Capsida Biotherapeutics / CRG AAV programs. In regenerative cell therapy specifically, Neurona's NRTX-1001 is the most advanced program, with competing cell-based approaches still in preclinical or early discovery stages, positioning NRTX-1001 as a near-category-of-one asset if pivotal data confirm the Phase 1/2 seizure-reduction signal and long-term durability. UCB's rationale combines its established epilepsy commercial infrastructure with a disease-modifying modality that is strategically orthogonal to its existing small-molecule ASM franchise.